Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
41 hedge funds and large institutions have $147M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 5 closing their positions.
7,813% more call options, than puts
Call options by funds: $5.3M | Put options by funds: $67K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
56% more capital invested
Capital invested by funds: $94.2M → $147M (+$52.5M)
28% more funds holding
Funds holding: 32 → 41 (+9)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.72M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.53M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$845K |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$510K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$385K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.93M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$856K |
| 3 |
Walleye Capital
New York
|
-$328K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$300K |
| 5 |
JP Morgan Chase
New York
|
-$195K |
STSA Hedge Fund Activity: Q3 2022 in Review
41 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q3 2022, worth a combined $147M — up 56% from $94.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new STSA positions and 5 closed out — a net gain of 9 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $9.72M. The largest seller was Ikarian Capital, cutting an estimated $2.93M.
- 41 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q3 2022, up from 32 in Q2 2022.
- Funds reported $147M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q3 2022, up 56% quarter-over-quarter.
- 14 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 5 closed out, a net change of +9 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Driehaus Capital Management, an estimated $9.72M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Ikarian Capital, an estimated $2.93M sold.
Based on aggregated 13F filings for Q3 2022.